Cartesian Therapeutics (RNAC) Non-Current Debt (2015 - 2023)

Cartesian Therapeutics (RNAC) has 8 years of Non-Current Debt data on file, last reported at $13.8 million in Q2 2023.

• On a quarterly basis, Non-Current Debt fell 39.09% year-over-year to $13.8 million in Q2 2023; TTM through Jun 2023 was $13.8 million, a 39.09% decrease from a year earlier, with the FY2022 full-year figure at $17.8 million, down 9.59% from the prior year.
• Non-Current Debt for Q2 2023 stood at $13.8 million, down from $16.2 million in the prior quarter.
• Over the last five years, Non-Current Debt for RNAC reached as high as $25.0 million in Q1 2022 and fell as low as $6.4 million in Q2 2020.
• Historically, Non-Current Debt has averaged $20.0 million across 4 years, with a median of $21.3 million in 2021.
• Across the five-year window, Non-Current Debt soared 255.57% in 2021 and slumped 39.09% in 2023, its largest moves.
• Year by year, Non-Current Debt stood at $24.8 million in 2020, then slipped by 20.65% to $19.7 million in 2021, then retreated by 9.59% to $17.8 million in 2022, then dropped by 22.48% to $13.8 million in 2023.
• Per Business Quant data, the three most recent Non-Current Debt figures were $13.8 million in Q2 2023, $16.2 million in Q1 2023, and $17.8 million in Q4 2022.